Background-To enable intravascular detection of inflammation in atherosclerosis, we developed a near-infrared fluorescence (NIRF) catheter-based strategy to sense cysteine protease activity during vascular catheterization. Methods and Results-The NIRF catheter design was based on a clinical coronary artery guidewire. In phantom studies of NIRF plaques, blood produced only a mild (Ͻ30%) attenuation of the fluorescence signal compared with saline, affirming the favorable optical properties of the NIR window. Catheter evaluation in vivo used atherosclerotic rabbits (nϭ11). Rabbits received an injection of a cysteine protease-activatable NIRF imaging agent (Prosense750; excitation/emission, 750/770 nm) or saline. Catheter pullbacks through the blood-filled iliac artery detected NIRF signals 24 hours after injection of the probe.
sclerosis link inflammation to plaque progression and complications. 1 Although several imaging methods can assess plaque structure, few can visualize specific molecular and cellular aspects of the inflammatory process. To address this need, rapidly developing molecular sensing strategies may permit visualization of key biological processes in atherosclerosis. 2, 3 
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In particular, near-infrared fluorescence (NIRF) detection strategies can visualize inflammatory processes in atheromata of small animals, including cysteine proteinase and matrix metalloproteinase activity. 4, 5 Given the role of altered protease activity in atheroma expansion and destabilization, 6 -8 visualization of atheroma protease activity in human subjects might identify inflamed, high-risk lesions associated with myocardial infarction. 9 To date, no readily translatable platform for the detection of NIRF signal from atheromata in vivo exists. To address this need, we have developed a flexible, narrow-diameter NIRF catheter to permit in vivo, intravascular NIRF sensing in human coronary artery-sized vessels. Here, we investigated the ability of the NIRF catheter to visualize protease activity indicative of inflammation in real time in vivo in rabbit atheromata, the effects of blood absorption on the in vivo NIRF signal, and the association between in vivo NIRF signals and histological measures of inflammation, specifically plaque cysteine proteases and macrophages. excitation wavelength of 750 nm (B&W TEK, Newark, Del) served as an excitation source. The excitation light was filtered with a narrow-bandpass interference filter centered at 752 nm and with a 5-nm full width at half-maximum to remove any residual laser scatter. Next, filtered excitation light was guided with a multimode fiber after passing through a 3-dB beam splitter and then coupled into a dedicated catheter prototype based on an optical coherence tomography wire (LightLab Imaging Inc, Westford, Mass). The catheter contains a 0.36-mm/0.014-in floppy radiopaque tip with a 0.41-mm/0.016-in OD housing a 62.5/125-m multimode fiber 200 cm long. The smaller diameter and greater flexibility represented a significant advance over our prior proof-of-principle NIRF catheter design with application limited to large-caliber ex vivo structures. 10 At the end of the catheter, a prism then directed the light at 90°with respect to the catheter and focused this light on a near diffractionlimited focal spot size of Ϸ40Ϯ15 m at a working distance of 2Ϯ1 mm ( Figure 1A ). Emitted fluorescent light was then collected back into the catheter and guided to the beam splitter, where one half of the photon flux was coupled into a separate multimode fiber. To limit contamination by backscattered light, fluorescence photons were filtered with a dielectrically coated dichroic filter with a cut-on wavelength of 780 nm. The residual fluorescence light was detected with a photomultiplier tube (H5783-20, Hamamatsu, Shizuoka, Japan) and then digitized with 16-bit resolution at 1 kHz (DAQ card, National Instruments, Austin, Tex) operating on a personal computer. Data noise reduction was performed with a 50-point moving average filter (MatLab version 7.5, MathWorks, Natick, Mass). The present studies typically used laser powers of 0.9 mW as measured by a power meter at the catheter tip, considerably lower than the 5to 15-mW power used in clinical optical coherence tomography systems. 11
Phantom Experiments
An atherosclerotic vessel phantom was designed that consisted of fresh whole rabbit blood, simulated tissue, and plaque ( Figure 1B) . The plaque was simulated with a cuvette filled with a solution of 1% intralipid (Liposyn, Hospira Inc, Lake Forest, Ill) and 50 ppm India ink. 12 The plaque was rendered fluorescent with an NIR fluorochrome (AF750, Molecular Probes, Inc, Eugene, Ore) at a concentration of 300 nmol/L. The overlying solid tissue phantom was made from a polyester casting resin (Castin'Craft, ETI, Fields Landing, Calif) mixed with TiO 2 (Sigma-Aldrich Chemical Co Inc, Milwaukee, Wis) and India ink (Faber-Castell, Cleveland, Ohio) 12 to mimic typical tissue optical properties in the NIR. 13 The optical parameters of the tissue were chosen to produce lower absorption and increased scattering compared with blood ( a ϭ0.4 cm Ϫ1 and Ј s ϭ12 cm Ϫ1 , Figure 1 . The NIRF catheter prototype. A, The catheter consists of a 0.36-mm/0.014-in floppy radiopaque tip with a maximum OD of 0.48 mm/0.019 in. The focal spot for the 90°arc-sensing catheter was 40Ϯ15 m at a working distance of 2Ϯ1 mm (arrow). B, Phantom for intravascular simulation measurements. Plaque (P) consists of intralipid plus India ink 50 plus AF750 (NIR fluorochrome); tissue (T; fibrous cap) consists of polyester casting resin plus titanium dioxide (TiO 2 ) plus India ink; the container (gray shaded area) was filled with fresh rabbit blood or saline. The catheter was immersed in fresh rabbit blood and positioned at a variable distance (D) from a fluorescent phantom representing the plaque (P). To mimic the presence of a fibrous cap, a solid tissue phantom of thickness T was interposed between the plaque and the lumen. C, Plot of the detected NIRF signal as a function of the distance D in the presence of blood (1/e signal decay, 500 m; ⅙) compared with saline (1/e signal decay, 700 m; ⅷ). Inset, The fluorescence signal decay in saline at distances up to 10 mm. D, Plot of the detected NIRF signal in blood in the presence of a tissue phantom (T) of thickness 500 m shows modest NIRF signal attenuation (Ͻ35%) vs the case in C where Tϭ0. respectively). The tissue thickness was varied to be 0 (no tissue phantom present) or 500 m.
The catheter was next immersed in the vessel phantom at a distance from the fluorescent plaque. The optical power at the exit of the catheter was kept fixed during all the measurements at 0.9 mW. The fluorescence intensity was recorded with the system described above.
Cysteine Protease-Activatable Imaging Agent
A cysteine protease-activatable NIRF agent with utility in atherosclerosis was used 4, 14 and scaled up for large-animal use (Prosense750; excitation/emission, 750 nm/780 nm; VisEn Medical, Woburn, Mass). The agent consists of multiple NIR fluorochromes linked to protected graft copolymer consisting of lysine-lysine bonds. At baseline, the agent is minimally fluorescent because of intramolecular quenching. The agent reports on cysteine proteases, including cathepsin B. 4, 14, 15 After cleavage by cysteine proteases, the backbone liberates smaller fragments with dequenched NIR fluorochromes, generating strong local fluorescence. For further details on this class of activatable imaging agents and the mechanism of NIRF signal generation, see the discussion by Jaffer et al. 16 
Atherosclerosis
New Zealand white rabbits (weight, 3 to 3.5 kg; Charles River Laboratories, Wilmington, Mass) underwent balloon denudation of iliac arteries and hypercholesterolemic diet to produce inflamed atheromata. Rabbits consumed a high-cholesterol diet (1% cholesterol and 5% peanut oil, C-30293, Research Diets, Inc, New Brunswick, NJ) for 1 week before balloon injury. After an overnight fast, anesthesia was induced with intramuscular ketamine (35 mg/kg) and xylazine (5 mg/kg). Anesthesia was continued with inhaled isoflurane (1% to 5% vol/vol, Baxter, Deerfield, Ill) and supplemental O 2 . Next, a 3F Fogarty arterial embolectomy catheter (Edwards Lifesciences, Irvine, Calif) was advanced into the common iliac vessels. The balloon was inflated to tension (0.6 to 1.0 mL). A total of 3 pullbacks were performed in the left and right iliac arteries and in the infrarenal aorta. After injury, the introducer was removed, and the left carotid artery was ligated. Rabbits continued on the highcholesterol diet for 4 to 8 weeks. Plasma cholesterol levels were measured with a commercial kit (Hemagen, Columbia, Md). Twenty-four hours before in vivo experiments, rabbits received the protease agent (600 nmol/kg) or saline intravenously. This postinjection time point was chosen on the basis of prior experimental results with protease-activatable agents in atherosclerosis. 4, 16 
Intravascular Sensing of NIRF Signals in Atherosclerosis
Anesthesia was initiated as above, and a 5F introducer was placed in the right carotid artery and then delivered to the descending thoracic aorta under fluoroscopic guidance. Intravenous heparin (150 U/kg) was administered next. A 5F balloon wedge catheter (Arrow International Inc, Reading, Pa) was placed through the sheath and advanced to the abdominal aorta, followed by aortoiliac angiography. The NIRF catheter was then advanced through the balloon wedge catheter into the distal iliac arteries. To limit sampling variability from the 90°sensing catheter, manual pullback of the catheter over 20 seconds was performed in each iliac artery 3 times. From each digitized pullback, the maximum voltage was recorded. From this set of maximum voltages, the maximal value was identified. The in vivo plaque target-to-background ratio (TBR) was thus calculated as maximum voltage detected from all pullbacks divided by background voltage.
To confirm that the augmented voltage was plaque specific, the catheter was readvanced to lesions with the angiogram and NIRF signal used as a roadmap. The static voltage was recorded adjacent to plaques and adjacent to the normal-appearing vessel wall on angiography. To assess the effect of blood absorption on the detected NIRF signal, balloon occlusion and saline flushing (3 mL over 4 seconds) were performed through the balloon wedge catheter (Arrow International Inc). Flushing and associated voltage traces were recorded in both areas of plaque and normal vessels. After completion of the experiment, rabbits were killed, and blood was obtained and anticoagulated (9 parts blood, 1 part 3.8% sodium citrate). The rabbit was then perfused with saline and 4% paraformaldehyde at physiological pressure. The institutional Subcommittee on Research Animal Care approved all animal protocols.
Ex Vivo Imaging
Resected atherosclerotic aortoiliac vessels underwent fluorescence reflectance imaging (FRI) with an excitation/emission filter of 762 nm/800 nm and a 5-second exposure time (BonSAI, Siemens, Erlangen, Germany). Light images also were obtained with an exposure time of 100 ms. Region-of-interest analysis was performed with visual identification of plaques and normal background on FRI images (Osirix version 2.7.5, A. Rosset). The plaque TBR was defined as plaque region-of-interest signal divided by adjacent vessel background region-of-interest signal).
Histopathology
After imaging, vessels were immersed in 4% paraformaldehyde for 24 hours. Vascular rings were then frozen in optical cutting temperature compound (Sakura Finetek, Torrance, Calif) for histopathological analysis. Serial 5-m cryosections of rabbit atheromata were cut. Immunohistochemistry was performed using the avidin-biotinperoxidase method. Briefly, sections treated with 0.3% hydrogen peroxide were incubated for 60 minutes with primary or isotype control antibodies, followed by the respective biotinylated secondary antibody. The reaction was visualized with aminoethylcarbazole substrate (Dako, Carpinteria, Calif) and counterstained with Harris hematoxylin solution. Immunoreactive cathepsin B was detected with a polyclonal goat anti-cathepsin B antibody (Santa Cruz Biotechnology, Santa Cruz, Calif). Plaque macrophages were identified with a mouse monoclonal antibody (Ab-5/RAM-11, Laboratory Vision, Fremont, Calif). Tissue sections were viewed with a microscope (Nikon Eclipse 50i, Tokyo, Japan), and images were captured with a CCD-SPOT RT digital camera (Diagnostic Instruments, Sterling Heights, Mich).
Fluorescence Microscopy
Cryosections (5 m) were obtained from fresh-frozen rabbit arteries. Fluorescence microscopy of plaque and normal vessel sections was performed with an upright epifluorescence microscope (Eclipse 80i, Nikon) that visualized the distribution of agent-specific NIRF (excitation, 673 to 748 nm; dichroic mirror, DM750; emission, 765 to 835 nm; exposure time, 5 seconds) and autofluorescence (excitation, 460 to 500 nm; dichroic mirror, DM505; emission, 510 to 560 nm; exposure time, 0.5 second).
Statistical Analysis
Data are presented as meanϮSE. Student t test was used to compare the mean TBR between the protease agent group and saline group for both in vivo and ex vivo fluorescence studies. Linear regression was performed with Prism version 4.0c (GraphPad Software, San Diego, Calif). A value of PϽ0.05 was considered statistically significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results

Light Attenuation in Blood and Tissue Phantoms In Vitro
Light attenuates considerably while traveling through opaque tissue, but the NIR window used here minimizes photon attenuation. Modeling of the effects of blood and tissue on NIRF signal attenuation used an atherosclerotic vessel wall phantom that consisted of fresh blood, simulated tissue, and NIRF plaque ( Figure 1B) . In vitro modulation of the distance, reflecting the blood volume between the catheter and the plaque, produced mild NIRF signal attenuation in the presence of blood, with a decay distance (1/e) of 500 m compared with a decay distance of 700 m in saline ( Figure  1C ). Modeling in the visible light range indicated significantly greater photon attenuation (data not shown). The tissue thickness, reflecting a simulated fibrous cap overlying the fluorescent plaque, showed instead only modest effects on the NIRF signal with a 500-m thickness ( Figure 1D) . These blood and tissue attenuation curves demonstrated feasibility of light detection through blood in the NIR window.
Delivery of the Intravascular NIRF Catheter in Atherosclerotic Vessels
Balloon injury of the iliac arteries, followed by hypercholesterolemia (average cholesterol, 1077Ϯ672 mg/dL), induced angiographically visible lesions with evident luminal narrowing (angiographic stenosis, 30% to 100% diameter; Figure 2A ). Total occlusions (100% stenosis) were noted in 3 of 22 (14%) of the injured iliac arteries. In patent arteries, the NIRF catheter was easily advanced bare wire through a 5F balloon wedge pressure catheter and selectively placed in the right or left iliac artery as desired ( Figure 2B ). Resected aortoiliac vessels after the imaging procedure showed bilateral yellowish-white atheromata in areas of balloon injury ( Figure 2C ).
Real-Time Intravascular Detection of NIRF Signals Through Flowing Blood
All animals tolerated injection of the protease-activatable agent; no adverse events were noted. To measure the plaque-associated NIRF signal in vivo, distal-to-proximal pullbacks of the iliac vessels and abdominal aorta were performed in each iliac artery (Figure 3 and Movie I of the online-only Data Supplement). Pullbacks were performed during flowing blood without occlusion or flushing. The maximal voltage was recorded from 3 distinct catheter pullbacks to maximize the sampled vessel area. Study of animals that received the cysteine protease-activatable agent yielded high levels of NIRF (voltage) (Figure 3 ). The augmented NIRF signal localized to plaques as assessed by x-ray angiographic correlation and by direct repositioning of the NIRF catheter at plaques defined by angiography. The peak in vivo plaque TBR was 6.8Ϯ1.9 in the protease agent group. In contrast, control animals showed minimal change in the baseline low NIRF signal during pullbacks (Figure 3 ). The peak in vivo plaque TBR was 1.3Ϯ0.3 (PϽ0.05), consistent with low plaque autofluorescence in the NIR window. 17 Overall, the protease-activatable agent produced a 558% higher plaque TBR than plaques from the saline group.
Distinctive NIRF Signal Profiles Further Distinguish Plaques From Normal-Appearing Vessels
To assess the specificity of plaque NIRF signal in the protease agent group, the catheter was readvanced to atheromata or normal-appearing segments as defined by the angiogram. Stationary recordings demonstrated augmented NIRF signal in the region adjacent to plaques compared with normal areas and showed that the NIRF signal was stable during physiological pulsatile blood flow (Figure 4 ). Modest quenching (Ͻ30% reduction in the fluorescence signal at 5 seconds of static catheter position) was observed at the power settings used. In addition, to determine the effects of blood absorption on the detected NIRF signal in both areas of plaques and normal segments of the protease agent group, balloon occlusion, followed by saline flushing, was performed. In the protease agent group only, differences in the flush profiles were noted between plaque areas and normal segments. In plaque areas, saline flushing augmented the detected NIRF signal (Figure 4) , with a peak signal increase of 74Ϯ18%. In contrast, in normal vessel segments, flushing modestly decreased the detected NIRF signal (Ϫ38Ϯ6% peak change; PϽ0.01 versus plaque signal changes). In control rabbits, minimal signal deviation in plaques or normal segments was detected during flushing ( Figure 4 ).
Ex Vivo FRI of Inflammation in Atheromata
In the protease agent group, macroscopic FRI revealed NIRF signal in plaques but not in the uninjured, normal-appearing vessel segments ( Figure 5 ). Control animals showed negligible NIRF signal from autofluorescence. The peak plaque TBR on FRI was 10.3Ϯ1.8 in the protease agent group, 857% higher than the peak plaque TBR in the control group (1.8Ϯ0.3; PϽ0.01). The in vivo and ex vivo peak plaque TBRs correlated well (rϭ0.82, PϽ0.01; Figure 6 ).
Colocalization of Microscopic NIRF Signal With Cysteine Protease and Macrophages
On fluorescence microscopy, plaque sections from the protease agent group revealed greater NIRF signal compared with sections from the control group, consistent with a low level of plaque autofluorescence at 800 nm (Figure 7 ). In addition, normal arterial segments from the protease group had relatively low NIRF signal, confirming that the proteaseactivatable agent enhanced atheromata selectively. The distinction between NIRF signal and autofluorescence was further evident on merged 2-channel fluorescence microscopy, which demonstrated green autofluorescence characteristic of elastin in all sections but only high NIRF signals in plaques from the protease agent group (Figure 7) .
Further histopathological analyses revealed colocalization of the NIRF signal with cell-rich areas composed primarily of macrophages (Figure 8 ). Immunohistochemical detection of cathepsin B, a lysosomal cysteine protease that activates the protease agent, 4, 14, 15 colocalized with plaque NIRF signal and plaque macrophages (Figures 7 and 8) . In contrast, minimal NIRF signal was noted in paucicellular areas of plaques. In addition, although plaques of control rabbits showed abundant macrophages and cathepsin B, minimal NIRF microscopic signal was present (data not shown). 
Discussion
The experimental results demonstrate the detectability of inflammation-associated proteinase activity in atherosclerosis in vivo in real time using a novel intravascular NIRF catheter-sensing approach. In vivo NIRF catheter signal detection, ex vivo FRI, and microscopic NIRF signals in atherosclerotic plaques colocalized with inflammation, spe-cifically augmented cysteine proteinase protein expression in macrophages.
Although assessment of protease activity in atheroma is feasible in mice via surgical exposure, 4,5 the present study used Augmented NIRF signal in atheromata in the protease agent group. A, The in vivo peak plaque TBR was 558% greater in the Prosense group vs saline (6.8Ϯ1.9 vs 1.3Ϯ0.27, respectively; PϽ0.05). B, The peak plaque TBR on ex vivo FRI was 856% greater in the Prosense group, with a TBR of 10.3Ϯ1.8 in the agent group vs 1.8Ϯ0.3 in the saline group (PϽ0.01). C, Correlation between the in vivo and ex vivo plaque TBR was significant (rϭ0.82, PϽ0.01). a novel intravascular NIRF catheter that detected plaque protease activity during catheterization of arteries of a caliber similar to human coronary arteries. Moreover, the catheter uses the same geometry and flexibility as an optical coherence tomography guidewire in use for clinical coronary arterial imaging. In addition, the current in vivo experiments demonstrated acquisition of endovascular NIRF signals through blood and during physiological blood flow as opposed to confocal microscopy approaches in which imaging is performed externally without blood interference. 16 This sensing platform visualized cysteine protease activity in real time in atherosclerotic plaques (average TBR Ͼ6) despite the presence of blood ( Figure  3 and Movie I in the online-only Data Supplement). Normal arterial segments in atherosclerotic or nonatherosclerotic rabbits yielded minimal NIRF catheter-detected signal. Three synergistic factors served to augment the in vivo plaque TBR: (1) an efficient, activatable NIRF molecular imaging agent; (2) operating in the NIR window for fluorescence signal detection (efficient photon penetration up to 7 to 14 cm in transillumination mode and low tissue autofluorescence); 17 and (3) a local catheter-based system to detect fluorescent plaque signals. From an imaging agent standpoint, the highly quenched proteaseactivatable agent emits negligible fluorescence when initially injected. Protease-mediated cleavage of the agent produces the fluorescent signal and results in high TBRs as a result of the low background signal. In addition, 1 enzyme molecule can cleave multiple substrate copies, augmenting the efficiency of this approach. Using the catalytic properties of enzymes provides amplification not possible with the 1-to-1 stoichiometry of imaging probes based on binding of labeled inhibitors.
Studies on a phantom demonstrated that NIRF signal detection remained efficient even in the presence of blood, with a decay distance (1/e) of 500 m compared with 700 m in saline. In vivo studies confirmed the ability to detect efficiently NIRF signals through blood without the need for flushing or balloon occlusion. Because the average iliac artery diameter is Ϸ2 to 2.5 mm, in a 50% diameter stenosis, a centered catheter should be Ϸ600 m away from a plaque, a distance that should readily allow NIRF signal detection ( Figure 1C ). Phantom measurements also demonstrated that saline displacement did not produce dramatic gains in the detected NIRF signal, as observed here in vivo ( Figure 4B ). Both the in vivo and phantom results suggest that the NIR window has utility for in vivo molecular imaging of atherosclerosis in vessels the size of human coronary arteries.
The NIRF signal in plaque sections was associated with both macrophages and the protease cathepsin B, a cysteine protease produced by macrophages that is a member of a proteinase family linked to atherosclerosis. 4,18 -20 By promoting plaque inflammatory cell recruitment, elastinolysis and collagenolysis, apoptosis, and neoangiogenesis, cysteine proteases such as cathepsin B play a pivotal role in promoting atheroma formation, expansion, and rupture. 6 -8 In the present study, cathepsin B colocalized strongly with macrophages and NIRF signal in rabbit atheromata, consistent with earlier murine atherosclerosis studies. 4, 14 In addition, cysteinyl proteinases such as cathepsin B readily cleave the protease-activatable agent substrate in vitro and in vivo. 4, 14, 15 The current molecular imaging and histopathological results in large animals strengthen the relationship between cysteine protease activity and atherosclerosis and further validate cysteine proteases as important imaging biomarkers of plaque inflammation.
This in vivo proof-of-principle study has certain limitations. Although the imaging agent is activated predominantly by cathepsin B, other proteases may activate the agent; additional studies may clarify their relative contributions in vivo. Additional specificity for cathepsin B, if necessary, could be obtained with second-generation designs of protease-activatable agents, as recently demonstrated for cathepsin K. 16 At present, the developed catheter senses fluorescence in 90°arcs in a 1-dimensional fashion, potentially missing focal spots of high NIRF signal. To reduce sampling error, multiple NIRF catheter pullbacks were performed in each artery. In addition, only the maximum voltage was used in the in vivo data analyses to limit error during manual pullback and showed good correlation between in vivo and ex vivo data (rϭ0.82). Additional study parameters subject to further optimization include the laser power, imaging agent dose, and ideal time delay for sensing after agent injection. Advances in NIRF catheter design should enable more complete imaging (via optical fiber rotation), uniform vessel wall sampling, and automated pullbacks. The fluorescence signals detected are heavily surface weighted; further studies will determine NIRF signal variation as a function of plaque thickness. Encouragingly, the present phantom studies suggest that overlying tissue (eg, fibrous cap) will not strongly attenuate the NIRF signal. Lastly, although in vivo NIRF signal detection may be favorable in the arteries studied (2-to 2.5-mm diameter), further studies will determine NIRF signal detection capability through larger volumes of blood, as found in larger vessels or with very mildly stenotic lesions.
These studies serve to form the basis for future clinical applications of this promising technology. The imaging agent, tested safely in medium-sized animals for the first time here, appears clinically favorable from a safety profile for 2 reasons. First, the polymer backbone of the agent has already been safely investigated in clinical trials. 21 Second, the NIR fluorochromes of the agent are similar to organic fluorochromes such as indocyanine green, an agent used widely in retinal angiography and for many decades in indicatordilution studies in humans that possesses a highly favorable safety profile. 22 In conjunction with Prosense, clinical development of NIRF catheter technology could enable coronary arterial applications such as identifying high-risk plaques harboring inflammation or assessing the biological effects of novel antiinflammatory agents on atheromata in vivo. In practice, this NIRF catheter approach could interrogate moderately stenotic coronary lesions of patients with anticipated high cardiovascular event rates such as those with established cardiovascular disease, as well as high-risk patient subsets with augmented coronary plaque inflammation such as diabetic patients. 23 Furthermore, integration of NIRF with other light-based imaging methods could yield integrated NIRFoptical coherence tomography, NIRF-optical frequency domain imaging, 24 or NIRF-NIR spectroscopy 25 catheters that enable simultaneous molecular and structural assessment of atherosclerosis in a real-time pullback fashion.
